Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025)
Legend Biotech (LEGN) reported Income from Continuing Operations of 30800000.0 for Q4 2025, down 43.69% on a YoY basis from 54700000.0 in Q4 2024, and up 180.09% quarter-over-quarter from 38457000.0 in Q3 2025.
Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Legend Biotech has reported Income from Continuing Operations for 7 years, with the latest figure at 30800000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 43.69% year-over-year to 30800000.0; the trailing twelve-month figure through Dec 2025 stood at 229217000.0 (down 64.58% YoY), and the FY2025 full-year result was 268400000.0, down 251.64% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 30800000.0, up from 38457000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 54700000.0 in Q4 2024, with the low at 198548000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 81917329.85 across 5 years, with a median of 89958500.0 in 2021.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 33686.45% — and 2024, when it jumped 137.26%.
- Legend Biotech's Income from Continuing Operations stood at 88334000.0 in 2021, then sank by 53.47% to 135570000.0 in 2022, then decreased by 8.29% to 146813994.0 in 2023, then jumped by 137.26% to 54700000.0 in 2024, then slumped by 43.69% to 30800000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 30800000.0 (Q4 2025), 38457000.0 (Q3 2025), and 124216000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30.80 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -97.34 Mn |
| Dec 31, 2024 | 54.70 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -59.78 Mn |
| Dec 31, 2023 | -146.81 Mn |
| Sep 30, 2023 | -62.78 Mn |
| Jun 30, 2023 | -198.55 Mn |
| Mar 31, 2023 | -111.85 Mn |
| Dec 31, 2022 | -135.57 Mn |
| Sep 30, 2022 | -84.65 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | -91.58 Mn |
| Mar 31, 2021 | -94,603.00 |